The PPAR gamma agonist troglitazone regulates erk 1/2 phosphorylation via a PPARγ-independent, MEK-dependent pathway in human prostate cancer cells

PPAR Research

Volumn , Issue , 2012, Pages

  Bolden, Adrienne ^a   Bernard, Lynikka ^a   Jones, Danielle ^a   Akinyeke, Tunde ^a,b   Stewart, Lamonica V ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 CHLORO 5 NITROBENZANILIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P21; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 84863414519     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/929052     Document Type: Article

References (45)

1. Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M., 15-deoxy-12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR Cell 1995 83 5 803 812 (Pubitemid 3006324)
2. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR ) Journal of Biological Chemistry 1995 270 22 12953 12956
3. Nolan J. J., Ludvik B., Beerdsen P., Joyce M., Olefsky J., Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone New England Journal of Medicine 1994 331 18 1188 1193 (Pubitemid 24331336)
4. Elstner E., Mller C., Koshizuka K., Williamson E. A., Park D., Asou H., Shintaku P., Said J. W., Heber D., Koeffler H. P., Ligands for peroxisome proliferator-activated receptory and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proceedings of the National Academy of Sciences of the United States of America 1998 95 15 8806 8811
5. Kim K. Y., Kim S. S., Cheon H. G., Differential anti-proliferative actions of peroxisome proliferator-activated receptor- agonists in MCF-7 breast cancer cells Biochemical Pharmacology 2006 72 5 530 540 (Pubitemid 44163294)
6. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., Safe S., Peroxisome proliferator-activated receptor agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor in MCF-7 breast cancer cells Cancer Research 2003 63 5 958 964 (Pubitemid 36278425)
7. Yin F., Wakino S., Liu Z., Kim S., Hsueh W. A., Collins A. R., Van Herle A. J., Law R. E., Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators Biochemical and Biophysical Research Communications 2001 286 5 916 922 (Pubitemid 32924859)
8. Chaffer C. L., Thomas D. M., Thompson E. W., Williams E. D., PPAR -independent induction of growth arrest and apoptosis in prostate and bladder carcinoma BMC Cancer 2006 6, article 53
9. Guan Y. F., Zhang Y. H., Breyer R. M., Davis L., Breyer M. D., Expression of peroxisome proliferator-activated receptor (PPAR ) in human transitional bladder cancer and its role in inducing cell death Neoplasia 1999 1 4 330 339
10. Leung W. K., Bai A., Chan V. Y. W., Yu J., Chan M. W. Y., To K. F., Wu J. R., Chan K. K., Fu Y. G., Chan F. K. L., Sung J. J. Y., Effect of peroxisome proliferator activated receptor ligands on growth and gene expression profiles of gastric cancer cells Gut 2004 53 3 331 338 (Pubitemid 38241325)
11. Lin M. S., Chen W. C., Bai X., Wang Y. D., Activation of peroxisome proliferator-activated receptor inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer Journal of Digestive Diseases 2007 8 2 82 88 (Pubitemid 46773619)
12. Takano S., Kubota T., Nishibori H., Hasegawa H., Ishii Y., Nitori N., Ochiai H., Okabayashi K., Kitagawa Y., Watanabe M., Kitajima M., Pioglitazone, a ligand for peroxisome proliferator-activated receptor- acts as an inhibitor of colon cancer liver metastasis Anticancer Research 2008 28 6 3593 3599
13. Yoshizumi T., Ohta T., Ninomiya I., Terada I., Fushida S., Fujimura T., Nishimura G. I., Shimizu K., Yi S., Miwa K., Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects International Journal of Oncology 2004 25 3 631 639
14. Akinyeke T. O., Stewart L. V., Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPAR -independent mechanism Cancer Biology and Therapy 2011 11 12 1046 1058
15. Lyles B. E., Akinyeke T. O., Moss P. E., Stewart L. V., Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPAR -dependent and PPAR -independent pathways Cell Cycle 2009 8 2 268 277
16. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D. S., Oh W., Demetri G., Figg W. D., Zhou X. P., Eng C., Spiegelman B. M., Kantoff P. W., Effects of ligand activation of peroxisome proliferator-activated receptor in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10990 10995
17. Shappell S. B., Gupta R. A., Manning S., Whitehead R., Boeglin W. E., Schneider C., Case T., Price J., Jack G. S., Wheeler T. M., Matusik R. J., Brash A. R., DuBois R. N., 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor and inhibits proliferation in PC3 prostate carcinoma cells Cancer Research 2001 61 2 497 503 (Pubitemid 32128606)
18. Kubota T., Koshizuka K., Williamson E. A., Asou H., Said J. W., Holden S., Miyoshi I., Koeffler H. P., Ligand for peroxisome proliferator-activated receptor (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Research 1998 58 15 3344 3352 (Pubitemid 28371075)
19. Panigrahy D., Singer S., Shen L. Q., Butterfield C. E., Freedman D. A., Chen E. J., Moses M. A., Kilroy S., Duensing S., Fletcher C., Fletcher J. A., Hlatky L., Hahnfeldt P., Folkman J., Kaipainen A., PPAR ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis Journal of Clinical Investigation 2002 110 7 923 932
20. Hisatake J. I., Ikezoe T., Carey M., Holden S., Tomoyasu S., Koeffler H. P., Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor in human prostate cancer Cancer Research 2000 60 19 5494 5498
21. Shiau C. W., Yang C. C., Kulp S. K., Chen K. F., Chen C. S., Huang J. W., Chen C. S., Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR Cancer Research 2005 65 4 1561 1569 (Pubitemid 40270186)
22. Radhakrishnan S. K., Gartel A. L., The PPAR- agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines Cell Cycle 2005 4 4 582 584 (Pubitemid 41359786)
23. Wei S., Lin L.-F., Yang C.-C., Wang Y.-C., Chang G.-D., Chen H., Chen C.-S., Thiazolidinediones modulate the expression of -catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor Molecular Pharmacology 2007 72 3 725 733 (Pubitemid 47347307)
24. Wei S., Yang H. C., Chuang H. C., Yang J., Kulp S. K., Lu P. J., Lai M. D., Chen C. S., A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells Journal of Biological Chemistry 2008 283 39 26759 26770
25. Wortzel I., Seger R., The ERK cascade: distinct functions within various subcellular organelles Genes and Cancer 2011 2 3 195 209
26. Mebratu Y., Tesfaigzi Y., How ERK1/2 activation controls cell proliferation and cell death is subcellular localization the answer? Cell Cycle 2009 8 8 1168 1175
27. Gioeli D., Mandell J. W., Petroni G. R., Frierson H. F., Weber M. J., Activation of mitogen-activated protein kinase associated with prostate cancer progression Cancer Research 1999 59 2 279 284 (Pubitemid 29048852)
28. Oka H., Chatani Y., Kohno M., Kawakita M., Ogawa O., Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state International Journal of Urology 2005 12 10 899 905 (Pubitemid 41726962)
29. Gardner O. S., Dewar B. J., Earp H. S., Samet J. M., Graves L. M., Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation Journal of Biological Chemistry 2003 278 47 46261 46269 (Pubitemid 37452196)
30. Baek S. J., Wilson L. C., Hsi L. C., Eling T. E., Troglitazone, a peroxisome proliferator-activated receptor (PPAR ) ligand, selectively induces the early growth response-1 gene independently of PPAR : a novel mechanism for its anti-tumorigenic activity Journal of Biological Chemistry 2003 278 8 5845 5853 (Pubitemid 36800831)
31. Kim K. H., Cho Y. S., Park J. M., Yoon S. O., Kim K. W., Chung A. S., Pro-MMP-2 activation by the PPAR agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK FEBS Letters 2007 581 17 3303 3310 (Pubitemid 46977368)
32. Chen F., Wang M., O'Connor J. P., He M., Tripathi T., Harrison L. E., Phosphorylation of PPAR via active ERK1/2 Leads to its physical association with p65 and inhibition of NF- Journal of Cellular Biochemistry 2003 90 4 732 744 (Pubitemid 37392464)
33. Li M., Lee T. W., Yim A. P. C., Mok T. S. K., Chen G. G., Apoptosis induced by troglitazone is both peroxisome proliterator-activated receptor- -and ERK-dependent in human non-small lung cancer cells Journal of Cellular Physiology 2006 209 2 428 438 (Pubitemid 44484634)
34. Chbicheb S., Yao X., Rodeau J.-L., Salamone S., Boisbrun M., Thiel G., Spohn D., Grillier-Vuissoz I., Chapleur Y., Flament S., Mazerbourg S., EGR1 expression: a calcium and ERK1/2 mediated PPAR -independent event involved in the antiproliferative effect of 15-deoxy-12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells Biochemical Pharmacology 2011 81 9 1087 1097
35. Adams M., Reginato M. J., Shao D., Lazar M. A., Chatterjee V. K., Transcriptional activation by peroxisome proliferator-activated receptor is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site Journal of Biological Chemistry 1997 272 8 5128 5132 (Pubitemid 27090069)
36. Camp H. S., Tafuri S. R., Regulation of peroxisome proliferator-activated receptor activity by mitogen-activated protein kinase Journal of Biological Chemistry 1997 272 16 10811 10816 (Pubitemid 27181096)
37. Hu E., Kim J. B., Sarraf P., Spiegelman B. M., Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR Science 1996 274 5295 2100 2103 (Pubitemid 27020707)
38. Moss P. E., Lyles B. E., Stewart L. V., The PPAR ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells Experimental Cell Research 2010 316 20 3478 3488
39. Sherr C. J., Roberts J. M., CDK inhibitors: positive and negative regulators of G1-phase progression Genes and Development 1999 13 12 1501 1512 (Pubitemid 29297917)
40. Weiss R. H., p21Waf1/Cip1 as a therapeutic target in breast and other cancers Cancer Cell 2003 4 6 425 429 (Pubitemid 38050039)
41. Yamada M., Horiguchi K., Umezawa R., Hashimoto K., Satoh T., Ozawa A., Shibusawa N., Monden T., Okada S., Shimizu H., Mori M., Troglitazone, a ligand of peroxisome proliferator-activated receptor-, stabilizes NUCB2 (nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene Endocrinology 2010 151 6 2494 2503
42. Papineni S., Chintharlapalli S., Safe S., Methyl 2-cyano-3,11-dioxo-18 -olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor- agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells Molecular Pharmacology 2008 73 2 553 565 (Pubitemid 351159224)
43. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., Seger R., Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor Molecular and Cellular Biology 2007 27 3 803 817 (Pubitemid 46174547)
44. Bae M. A., Song B. J., Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells Molecular Pharmacology 2003 63 2 401 408 (Pubitemid 36158376)
45. Yin F., Bruemmer D., Blaschke F., Hsueh W. A., Law R. E., Van Herle A. J., Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells Oncogene 2004 23 26 4614 4623 (Pubitemid 38850409)